Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENTAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus GENTAK.
AMIKACIN SULFATE vs GENTAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic